Literature DB >> 20614470

Hormonal contraceptives for contraception in overweight or obese women.

Laureen M Lopez1, David A Grimes, Mario Chen-Mok, Carolyn Westhoff, Alison Edelman, Frans M Helmerhorst.   

Abstract

BACKGROUND: Obesity has reached epidemic proportions around the world. Metabolic changes in obesity and greater body mass may lead to reduced effectiveness of hormonal contraceptives, such as the skin patch, vaginal ring, implants, and injectables. We systematically reviewed the evidence on the effectiveness of hormonal contraceptives among overweight and obese women.
OBJECTIVES: To examine the effectiveness of hormonal contraceptives in preventing unplanned pregnancies among women who are overweight or obese versus women of lower weight or body mass index (BMI). SEARCH STRATEGY: We searched MEDLINE, CENTRAL, POPLINE, EMBASE, ClinicalTrials.gov, and ICTRP. We also contacted investigators to identify other trials. SELECTION CRITERIA: All study designs were eligible. Any type of hormonal contraceptive could have been examined. The primary outcome was pregnancy. Overweight or obese women must have been identified by an analysis cutoff for weight or BMI (kg/m(2)). DATA COLLECTION AND ANALYSIS: Data were abstracted by two authors; life-table rates were included where available. For dichotomous variables, we computed an odds ratio with 95% confidence interval. The main comparisons were between overweight or obese women and women of lower weight or BMI. MAIN
RESULTS: We found 7 reports with data from 11 trials that included 39,531 women. One of three studies using BMI found a higher pregnancy risk for overweight or obese women. In the trial of two combination oral contraceptives, women with BMI >= 25 had greater pregnancy risk compared to those with BMI < 25 (OR 1.91; 95% CI 1.01 to 3.61). Among skin patch users, body weight was associated with pregnancy (reported P < 0.001) but BMI was not. Studies of a vaginal ring (never marketed) and a six-rod implant showed higher pregnancy rates for women weighing >= 70 kg versus those weighing < 70 kg (reported P values: 0.0013 and < 0.05, respectively). However, two implant studies showed no trend by body weight, and trials of an injectable had no pregnancies. AUTHORS'
CONCLUSIONS: Body weight addresses overall body size, while BMI generally reflects the amount of fat. Only one of three studies using BMI found a higher pregnancy risk for overweight women. The efficacy of implants and injectable contraceptives may be unaffected by body mass. The field could use trials of contraceptive methods with groups stratified by BMI. The current evidence on effectiveness by BMI is limited. However, the contraceptive methods examined here are still among the most effective when the recommended regimen is followed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20614470     DOI: 10.1002/14651858.CD008452.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  13 in total

Review 1.  Progestin-only contraceptives: effects on weight.

Authors:  Laureen M Lopez; Alison Edelman; Mario Chen-Mok; James Trussell; Frans M Helmerhorst
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 2.  Contraception and the obese woman.

Authors:  Elizabeth Reifsnider; Nonie Mendias; Yolanda Davila; Jennie Bever Babendure
Journal:  J Am Assoc Nurse Pract       Date:  2013-02-27       Impact factor: 1.165

Review 3.  [Gender Obesity Report--Influence of obesity on Reproduction and Pregnancy].

Authors:  Jürgen Harreiter; Alexandra Kautzky-Willer
Journal:  Wien Med Wochenschr       Date:  2015-12-09

4.  Class III obesity and unwanted pregnancy among women with live births in New York City, 2004-2007.

Authors:  Samantha Garbers; Mary Ann Chiasson
Journal:  Matern Child Health J       Date:  2013-10

Review 5.  Obesity and hormonal contraceptive efficacy.

Authors:  Jennifer A Robinson; Anne E Burke
Journal:  Womens Health (Lond)       Date:  2013-09

Review 6.  Safety and efficacy of contraception--Why should the obese woman be any different?

Authors:  Maria I Rodriguez; Alison B Edelman
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

Review 7.  Understanding obesity and endometrial cancer risk: opportunities for prevention.

Authors:  Rosemarie E Schmandt; David A Iglesias; Ngai Na Co; Karen H Lu
Journal:  Am J Obstet Gynecol       Date:  2011-06-07       Impact factor: 8.661

Review 8.  Putting risk into perspective: the US medical eligibility criteria for contraceptive use.

Authors:  Kathryn M Curtis; Naomi K Tepper; Polly A Marchbanks
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

9.  Association between body mass index, sexually transmitted infections, and contraceptive compliance.

Authors:  Andrea L DeMaria; Jonathan M Lugo; Mahbubur Rahman; Richard B Pyles; Abbey B Berenson
Journal:  J Womens Health (Larchmt)       Date:  2013-10-04       Impact factor: 2.681

10.  Levonorgestrel Intrauterine Device Use in Overweight and Obese Women.

Authors:  Lynne Y Saito-Tom; Reni A Soon; Sara C Harris; Jennifer Salcedo; Bliss E Kaneshiro
Journal:  Hawaii J Med Public Health       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.